^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    exemestane

    i
    Other names: FCE 24304, PNU 155971
    Company:
    Generic mfg.
    Drug class:
    Aromatase inhibitor
    Related drugs:
    7d
    A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE) (clinicaltrials.gov)
    P3, N=460, Not yet recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd.
    New P3 trial • Metastases
    |
    everolimus • fulvestrant • exemestane • SCR-6852
    8d
    TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2026 --> Jun 2025
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane
    11d
    Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial (clinicaltrials.gov)
    P3, N=1156, Not yet recruiting, Alliance for Clinical Trials in Oncology
    New P3 trial
    |
    tamoxifen • letrozole • anastrozole • exemestane
    15d
    Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (clinicaltrials.gov)
    P2, N=120, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    everolimus • fulvestrant • exemestane • Welireg (belzutifan)
    18d
    RaPhLRR: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, Oana Danciu | Active, not recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane
    18d
    ELEGANT: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (clinicaltrials.gov)
    P3, N=4220, Recruiting, Stemline Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    tamoxifen • letrozole • anastrozole • exemestane • Orserdu (elacestrant)
    25d
    MORPHEUS: A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=138, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tamoxifen • Verzenio (abemaciclib) • fulvestrant • ipatasertib (RG7440) • exemestane • Jingzhuda (entinostat)
    30d
    A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) (clinicaltrials.gov)
    P3, N=320, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2024 --> Mar 2026
    Enrollment closed • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ESR1 mutation • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation
    |
    everolimus • tamoxifen • fulvestrant • dexamethasone • exemestane • giredestrant (GDC-9545)
    1m
    PERFORM: First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting. (clinicaltrials.gov)
    P=N/A, N=1900, Recruiting, Pfizer | Trial completion date: Apr 2028 --> Mar 2029
    Trial completion date • HEOR • Combination therapy • Real-world evidence • Real-world • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • fulvestrant • exemestane
    1m
    EvoPAR-BR01: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=500, Recruiting, AstraZeneca | Trial completion date: Jul 2030 --> Oct 2030
    Trial completion date
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane • camizestrant (AZD9833) • saruparib (AZD5305)
    1m
    Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial. (PubMed, Sci Rep)
    P2; Sunitinib plus exemestane was associated with substantial yet reversible toxicities, providing safety, efficacy and biological impact insights of combining an antiangiogenic drug with hormone therapy in early-stage breast cancer.Trial registration: Registered with ClinicalTrials.gov, NCT00931450. 02/07/2009.
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • KDR (Kinase insert domain receptor) • FOXC1 (Forkhead Box C1) • SFRP1 (Secreted frizzled related protein 1)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    sunitinib • exemestane
    1m
    Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Jan 2027 --> May 2027
    Trial primary completion date • Metastases
    |
    everolimus • fulvestrant • exemestane • Welireg (belzutifan)
    1m
    A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced, Recurrent Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, OHSU Knight Cancer Institute
    New P2 trial • Metastases
    |
    Lynparza (olaparib) • Tagrisso (osimertinib) • carboplatin • gefitinib • gemcitabine • paclitaxel • temozolomide • tamoxifen • Verzenio (abemaciclib) • pemetrexed • fulvestrant • letrozole • pegylated liposomal doxorubicin • exemestane • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    1m
    BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov)
    P2, N=620, Recruiting, Fudan University | N=140 --> 620
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    Avastin (bevacizumab) • sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • SHR-A2102 • SHR-A1921 • SHR-A2009
    1m
    EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P3; Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    Guardant360® CDx
    |
    fulvestrant • letrozole • anastrozole • exemestane • Orserdu (elacestrant)
    1m
    DISCORDANT: A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-negative Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=504, Not yet recruiting, Danish Breast Cancer Cooperative Group | Phase classification: P4 --> P3 | N=250 --> 504
    Phase classification • Enrollment change
    |
    tamoxifen • Enhertu (fam-trastuzumab deruxtecan-nxki) • Verzenio (abemaciclib) • Kisqali (ribociclib) • exemestane
    1m
    A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (clinicaltrials.gov)
    P4, N=130, Completed, German Breast Group | Recruiting --> Completed | Trial completion date: Mar 2023 --> Aug 2024 | Trial primary completion date: Mar 2023 --> Aug 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Ibrance (palbociclib) • paclitaxel • tamoxifen • capecitabine • fulvestrant • letrozole • epirubicin • vinorelbine tartrate • exemestane
    2ms
    RaPhLRR: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (clinicaltrials.gov)
    P2, N=200, Active, not recruiting, Oana Danciu | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane
    2ms
    Computational studies and structural insights for discovery of potential natural aromatase modulators for hormone-dependent breast cancer. (PubMed, Bioimpacts)
    From molecular docking and analysis of interactions with the amino acid residues of the binding cavity, it was found that the amino acid residues interacting with the non-steroidal inhibitors exhibited π-stacking interactions with PHE134, PHE 221, and TRP 224, while the steroidal drug exemestane lacked π-stacking interactions...Additionally, anthraquinone compounds with minor structural modification can also serve to be potential aromatase inhibitors. The in silico protocol utilised can be useful in the drug discovery process for development of new leads from structurally diverse set of natural products that are comparable to the drugs used clinically in breast cancer therapy.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    exemestane
    2ms
    Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=60, Suspended, University of Washington | Recruiting --> Suspended
    Trial suspension • Metastases
    |
    tamoxifen • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane
    2ms
    A Randomised Trial Comparing Molecular Guided Treatment to Physician's Choice in Discordant ER-positive/HER2-negative Metastatic Breast Cancer (clinicaltrials.gov)
    P4, N=250, Not yet recruiting, Danish Breast Cancer Cooperative Group
    New P4 trial • Metastases • Discordant
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • carboplatin • docetaxel • tamoxifen • Perjeta (pertuzumab) • albumin-bound paclitaxel • exemestane
    2ms
    Case report: Clinicopathological characteristic of two cases of primary endometrial squamous cell carcinoma and review of the literature. (PubMed, Front Oncol)
    There are two main patterns of P16 and P53 expression, P16-positive/P53 wild-type and P16-negative/P53-mutant, but no positive expression of both has been seen so far. It is worth noting that we reported the second case of PESCC with a history of breast cancer, where the patient had been taking the oral aromatase inhibitor drug (exemestane) for a long period of time to reduce the estrogen level, indicating the low estrogen level may be also a key factor in the pathogenesis of PESCC.
    Review • Journal
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • TP63 (Tumor protein 63) • PAX8 (Paired box 8)
    |
    TP53 mutation • TP53 wild-type • ER negative • CDKN2A negative • TP53 expression • PGR expression
    |
    exemestane
    2ms
    MORPHEUS: A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=138, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2024 --> Sep 2024
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tamoxifen • Verzenio (abemaciclib) • fulvestrant • ipatasertib (RG7440) • exemestane • Jingzhuda (entinostat)
    2ms
    PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, Medical College of Wisconsin | Trial completion date: Jul 2024 --> Mar 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PGR positive
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    2ms
    PIKASSO-01: A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (clinicaltrials.gov)
    P1, N=193, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting | N=400 --> 193
    Enrollment closed • Enrollment change • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 negative • PIK3CA mutation • PIK3CA H1047R
    |
    paclitaxel • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • imlunestrant (LY3484356) • LOXO-783
    2ms
    MORPHEUS: A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=138, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2024 --> Sep 2024
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tamoxifen • Verzenio (abemaciclib) • fulvestrant • ipatasertib (RG7440) • exemestane • Jingzhuda (entinostat)
    3ms
    Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=247, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
    |
    Xtandi (enzalutamide capsule) • exemestane
    3ms
    EvoPAR-BR01: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=500, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Initiation date: Apr 2024 --> Aug 2024
    Enrollment open • Trial initiation date • Metastases
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane • camizestrant (AZD9833) • saruparib (AZD5305)
    3ms
    POWER: Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer (clinicaltrials.gov)
    P2, N=83, Active, not recruiting, Shayna Showalter, MD | Trial primary completion date: Mar 2024 --> Jun 2024
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    tamoxifen • letrozole • anastrozole • exemestane
    3ms
    Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. (PubMed, JAMA Oncol)
    These individuals were randomized to receive 5 years of adjuvant tamoxifen alone, tamoxifen plus OFS, or exemestane plus OFS. The benefit from OFS-containing adjuvant endocrine therapy was greater for patients with BCI(H/I)-low tumors than BCI(H/I)-high tumors. BCI(H/I)-low status may identify premenopausal patients who are likely to benefit from this more intensive endocrine therapy.
    Journal
    |
    HOXB13 (Homeobox B13) • IL17RB (Interleukin 17 Receptor B)
    |
    Breast Cancer Index®
    |
    tamoxifen • exemestane
    3ms
    POLAR: Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (clinicaltrials.gov)
    P3, N=400, Recruiting, ETOP IBCSG Partners Foundation | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    Ibrance (palbociclib) • tamoxifen • fulvestrant • exemestane
    3ms
    Initiation of Oral Endocrine Therapy and Survival Benefit Among Women with Early-Stage Breast Cancer. (PubMed, J Womens Health (Larchmt))
    Beneficiaries who initiated tamoxifen, anastrozole, letrozole, or exemestane within 3 months after cancer diagnosis were defined as initiators (n = 24,289), and those who never initiated these treatments were noninitiators (n = 8,899). ET initiation and adherence was associated with reduced risk of all-cause (adjusted HR = 0.62, 0.59-0.66; HR = 0.55, 0.53-0.59; respectively) and breast cancer related (adjusted HR = 0.57, 0.50-0.64; HR = 0.41, 0.36-0.47; respectively) mortality compared with noninitiators. Women with early-stage breast cancer who initiate ET and are adherent to treatment may achieve survival benefits compared with noninitiators.
    Journal
    |
    ER (Estrogen receptor)
    |
    tamoxifen • letrozole • anastrozole • exemestane
    3ms
    Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Merck Sharp & Dohme LLC | Trial completion date: May 2028 --> Sep 2028 | Trial primary completion date: Jun 2027 --> Jan 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    everolimus • fulvestrant • exemestane • Welireg (belzutifan)
    3ms
    The Antioxidant and HDAC-Inhibitor α-Lipoic Acid Is Synergistic with Exemestane in Estrogen Receptor-Positive Breast Cancer Cells. (PubMed, Int J Mol Sci)
    α-lipoic acid increases mitochondrial fusion and the expression of apoptosis-related proteins p21, APAF-1, BIM, FOXO1, and decreases expression of anti-apoptotic proteins survivin, BCL-2, and c-myc. In conclusion, combining exemestane with α-lipoic acid is a promising novel treatment option for ER-positive breast cancer.
    Journal • IO biomarker
    |
    ER (Estrogen receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BIRC5 (Baculoviral IAP repeat containing 5) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • APAF1 (Apoptotic peptidase activating factor 1)
    |
    exemestane
    3ms
    The role of everolimus in metastatic breast cancer and possibilities of moving forward-a narrative review. (PubMed, Ann Transl Med)
    One of the treatment options is the combination of everolimus with exemestane or other endocrine drug in later lines mainly based on progression-free survival (PFS) results of the phase 3 BOLERO-2 trial. I summarized the search results in this concise and brief report focusing on main trial results and ongoing research with everolimus. The most promising research directions seem to be further investigations for useable predictive biomarkers, for combinations with other targeted drugs (even in a triple combination) and for the feasibility of pharmacologically guided dosing method.
    Review • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    everolimus • exemestane
    3ms
    OVELIA: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (clinicaltrials.gov)
    P3, N=250, Recruiting, Tolmar Inc. | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    tamoxifen • letrozole • anastrozole • exemestane • Eligard (leuprolide acetate)
    3ms
    Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules. (PubMed, J Natl Cancer Inst)
    In contrast, a dose-response trend was observed in cancer tissue. Based on estradiol suppression in non-malignant tissue, lower exemestane schedules should be explored for breast cancer preventive therapy.
    Journal
    |
    ER (Estrogen receptor)
    |
    exemestane
    3ms
    Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (clinicaltrials.gov)
    P3, N=608, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2024 --> Jun 2025
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    exemestane • Jingzhuda (entinostat) • goserelin acetate
    3ms
    TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, Mayo Clinic | Trial completion date: Jul 2024 --> Dec 2025
    Trial completion date • Combination therapy • Metastases
    |
    Herceptin (trastuzumab) • paclitaxel • fulvestrant • letrozole • anastrozole • exemestane • Trazimera (trastuzumab-qyyp) • denifanstat (TVB-2640)
    4ms
    Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score (clinicaltrials.gov)
    P2; Trial completion date: Jan 2030 --> Jul 2031 | Trial primary completion date: Jul 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    tamoxifen • fulvestrant • anastrozole • exemestane • goserelin acetate
    4ms
    Pre-Operative Window of ET to Inform RT Decisions (POWER II) (clinicaltrials.gov)
    P3, N=284, Recruiting, University of Virginia | Not yet recruiting --> Recruiting
    Enrollment open
    |
    tamoxifen • letrozole • anastrozole • exemestane
    4ms
    Pre-Operative Window of ET to Inform RT Decisions (POWER II) (clinicaltrials.gov)
    P3, N=284, Not yet recruiting, University of Virginia
    New P3 trial
    |
    tamoxifen • letrozole • anastrozole • exemestane